Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Neutral 0

Viatris CFO Mistras Departs for Edwards Lifesciences

AI-generated analysis

πŸ‘©β€πŸ’Ό Theodora Mistras is departing her role as CFO at Viatris to join Edwards Lifesciences in the same position.

πŸ“… She will remain with Viatris until May 22, with her new role starting at the end of May.

πŸ›οΈ Mistras serves as Viatris' CFO since 2024 after previously working in healthcare investment banking at Citigroup Global Markets and Goldman Sachs.

⚑ At Edwards Lifesciences, she will succeed Scott Ullem, who is transitioning out of the CFO role after October planning.

πŸ’° Edwards Lifesciences has agreed to a base salary of $925,000 plus an approximately $2 million sign-on bonus for Mistras.

πŸ‘¨β€πŸ’Ό Viatris has named Paul Campbell as interim CFO effective May 8 while searching for a permanent successor.

🧾 Campbell was promoted from Chief Accounting Officer and Corporate Controller roles at the company.

🏒 Campbell joined Viatris' legacy company, Mylan, in 2002 after earlier working at Deloitte & Touche.

Bullish Signals
  • Viatris has secured a proven executive, Theodora Mistras, to take over as permanent CFO once her interim tenure concludes at the end of May.
  • Interim Chief Accounting Officer Paul Campbell, who joined legacy company Mylan in 2002, will lead Viatris starting May 8 while a permanent successor is sought.
  • Campbell brings extensive industry experience with early career stints at Deloitte & Touche and having worked within the company since its origins.
Risk Factors
  • Viatris is facing executive instability with the departure of its CFO, Theodora Mistras, who leaves to join competitor Edwards Lifesciences.
  • Mistras has been CFO since 2024, indicating a relatively short tenure before departing for a rival firm, which could signal internal dissatisfaction or strategic drift.
  • Viatris is left scrambling to find a permanent successor after only appointing Paul Campbell as interim Chief Accounting Officer and Corporate Controller effective May 8.
  • Paul Campbell's new role was filled immediately on an interim basis while the company searches for a permanent CFO, highlighting immediate leadership vacuum risks.
  • The departure of Mistras just weeks before her transition to Edwards Lifescences creates uncertainty over financial continuity at Viatris until May 22.
Full Analysis
Viatris chief financial officer Theodora Mistras will leave her current role to join Edwards Lifesciences as CFO starting at the end of May. Mistras, who has held the position since 2024, is scheduled to remain with Viatris until May 22 to ensure a smooth transition. Her compensation package at Edwards Lifesciences includes a base salary of $925,000, a sign-on bonus of approximately $2 million paid immediately upon start, plus additional stock and equity awards. She will be succeeding Scott Ullem, who previously announced in October his intention to transition from the role at Edwards Lifesciences. Viatris has appointed Paul Campbell as interim CFO effective May 8 while the company searches for a permanent replacement. Campbell, currently serving as Chief Accounting Officer and Corporate Controller, has been with Viatris's legacy company Mylan since 2002 and previously worked at Deloitte & Touche. The leadership change represents significant movement in the healthcare sector as executives shift between major pharmaceutical and medical device firms.